George Simeon, CEO of Curevo Vaccine, has over 25 years of experience in the healthcare sector working with multinational firms, start-ups, and not-for-profits. He has worked in pharmaceuticals, medical devices, IVD, and healthcare convergence technologies.
Before moving to the USA, he was based in South Korea from 2014-2018, where he worked for SK Telecom’s Healthcare Division in M&A and global strategic alliances in IVD and digital healthcare technologies.
He has worked across Europe and the USA as an executive with Johnson & Johnson, as Vice-President for Cordis Neurovascular Europe, and with GHX Europe as Commercial Vice-President. He also spent several years with Novartis Global Headquarters in Switzerland working on Health Economics and Pricing in their CNS and Cardiovascular portfolio.
George has founded two start-ups and advised companies on their entry and expansion into the Healthcare sector.
George is a graduate of INSEAD (MBA) and Yale University (MPH).
Before moving to the USA, he was based in South Korea from 2014-2018, where he worked for SK Telecom’s Healthcare Division in M&A and global strategic alliances in IVD and digital healthcare technologies.
He has worked across Europe and the USA as an executive with Johnson & Johnson, as Vice-President for Cordis Neurovascular Europe, and with GHX Europe as Commercial Vice-President. He also spent several years with Novartis Global Headquarters in Switzerland working on Health Economics and Pricing in their CNS and Cardiovascular portfolio.
George has founded two start-ups and advised companies on their entry and expansion into the Healthcare sector.
George is a graduate of INSEAD (MBA) and Yale University (MPH).
Speaking In
[Available On-Demand]
2020 BIO Investor Forum Buzz of BIO Finalist
Curevo Vaccine is a US-based clinical stage biotech…